Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium (Q42905241)

From Wikidata

Jump to navigation Jump to search

scientific article published on July 1, 2010

Language	Label	Description	Also known as
English	Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium	scientific article published on July 1, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 November 2017

Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 November 2017

Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium (English)

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

1 reference

based on heuristic

inferred from title

8

object named as

Amit M. Oza

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20847613

14 July 2024

author name string

Laurie Elit

3

1 reference

Europe PubMed Central

PubMed publication ID

10 November 2017

Lisa Wang

5

1 reference

Europe PubMed Central

PubMed publication ID

10 November 2017

Katrina Macalpine

6

1 reference

Europe PubMed Central

PubMed publication ID

10 November 2017

Stephen A. Welch

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20847613

14 July 2024

Hal W. Hirte

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20847613

14 July 2024

Russel J. Schilder

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20847613

14 July 2024

John J. Wright

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20847613

14 July 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20847613

14 July 2024

publication date

1 July 2010

1 reference

Europe PubMed Central

PubMed publication ID

10 November 2017

full work available at URL

http://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2FIGC.0b013e3181e273a8

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

https://syndication.highwire.org/content/doi/10.1111/IGC.0b013e3181e273a8

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

International Journal of Gynecological Cancer

1 reference

Europe PubMed Central

PubMed publication ID

10 November 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

10 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

10 November 2017

787-793

1 reference

Europe PubMed Central

PubMed publication ID

10 November 2017

Reactivity of a monoclonal antibody with human ovarian carcinoma

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1172/JCI110380

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]

1

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

2

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice

3

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma

4

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

5

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Sorafenib in advanced clear-cell renal-cell carcinoma

6

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

7

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

8

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

9

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use

10

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Optimal two-stage designs for phase II clinical trials

11

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients

12

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

13

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

14

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Phase II study of gemcitabine in ovarian cancer

15

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer

16

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer

17

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

18

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

19

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

The myth of measurable disease in ovarian cancer.

21

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II Trials

22

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

23

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

24

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

25

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia

26

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

27

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

28

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

29

1 reference

10.1111/IGC.0B013E3181E273A8

https://api.crossref.org/works/10.1111/IGC.0B013E3181E273A8

14 July 2024

Identifiers

10.1111/IGC.0B013E3181E273A8

1 reference

Europe PubMed Central

PubMed publication ID

10 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42905241&oldid=2204512272"